Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________

FORM 8-K
CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)
May 24, 2007
 
Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
 
Washington
0-23930
91-1549568
(State or other jurisdiction
of incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)
 
1100 Olive Way, Suite 100, Seattle, Washington
98101
(Address of principal executive offices)
(Zip Code)
 
Registrant's telephone number, including area code
(206) 623-7612
 
Not Applicable
(Former name or former address if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 8.01. Other Events.

On May 24, 2007, Targeted Genetics Corporation announced that it had achieved its enrollment target of 120 patients in its ongoing Phase I/II clinical trial of tgAAC94. A copy of the press release announcing this achievement and describing the Phase I/II trial is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
 
Item 9.01. Financial Statements and Exhibits.

    Exhibits.
99.1
Press Release of Targeted Genetics Corporation dated May 24, 2007.
 
 
 
 
 
SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
Targeted Genetics Corporation
 
By:  
/s/ David J. Poston
   
David J. Poston 
   
Vice President and
Chief Financial Officer 

Dated: May 24, 2007

 
 
 

INDEX TO EXHIBITS

Exhibit
Number
Description
99.1
Press Release of Targeted Genetics Corporation dated May 24, 2007